Kemira expands production capacity at San Giorgio site in Italy

Kemira Oyj
Press release
October 16, 2014 at 3.30 pm (CET+1)

Kemira will make a multimillion investment in a production line expansion of process and functional chemistries at San Giorgio site in Italy. The production starts in the beginning of the year 2015 and reaches the full production capacity by the end of March, 2015.

"San Giorgio investment secures us a sustainable and cost effective manufacturing capability and we can effectively fulfill our customer needs and requirements in terms of strength aids and tissue specialties", says Roberto Zulian, Manager, Business Development, EMEA. "The strategic location of the plant ensures our ability to efficiently serve all the major European tissue and board customers, especially in Italy, Germany, Eastern European countries, Turkey and the Middle East."

The investment includes two separate production lines for anionic and cationic products which will produce FennoBond strength chemistries for tissue and also board customers. FennoBond technologies enhance tissue paper dry and wet tensile, and are most typically used for home towel, napkin and handkerchief consumer products. The key Kemira products include FennoBond 3300E, FennoBond 46 and FennoBond 85E.

"Kemira's San Giorgio investment is an important step in becoming a significant supplier for the tissue industry in EMEA region", says Antti Matula, Head of Marketing & Product Lines, Paper, EMEA. "This investment ensures delivery of high quality products to Kemira's valued customers."

For more information, please contact


Kemira Oyj
Roberto Zulian, Manager, Business Development, EMEA
+39 335 603 9824

Antti Matula, Head of Marketing & Product Lines, Paper, EMEA
+49 171 196 1641

Kemira is a global chemicals company serving customers in water-intensive industries. We provide expertise, application know-how and chemicals that improve our customers' water, energy and raw material efficiency. Our focus is on pulp & paper, oil & gas, mining and water treatment. In 2013, Kemira had annual revenue of EUR 2.2 billion and around 4,500 employees. Kemira shares are listed on the Nasdaq OMX Helsinki Ltd.
www.kemira.com